⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for OctavaPink for Women With Dense Breast After Negative Mammography

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: OctavaPink for Women With Dense Breast After Negative Mammography

Official Title: OctavaPink® For Dense Breast After Negative Mammography

Study ID: NCT02209389

Conditions

Breast Cancer

Interventions

MRI

Study Description

Brief Summary: The OctavaPink test is indicated as an adjunct to mammography for breast cancer screening in asymptomatic women for whom screening or diagnostic mammography findings are normal or benign (BIRADS assessment category 1 or 2) and breast tissue is dense (BIRADS composition/density 3 or 4). The device is intended to increase breast cancer detection in the described patient population. Based upon the result of OctavaPink, the patient will be further evaluated by their physician.

Detailed Description: This is a multicenter, prospective study containing 3 parts: Part 1 consists of Part 1A (optimization/training) and Part 1B (evaluation/testing) as follows: Part 1A will optimize the OctavaPink test for women with dense breast tissue, and will not affect the treatment of the participants. Part 1A is an internal part done by EventusDx and no statistical evaluation is needed. Objectives: To optimize the OctavaPink test, with the target of ≥95% specificity and ≥70% sensitivity. Part 1B will assess the properties of the OctavaPink test using cases and controls obtained via the same criteria as in Part 1A. The sensitivity and specificity of the OctavaPink test must be confirmed as sufficiently high in samples in which EventusDx is blind to case/control status before using the test to affect clinical management of patients. Objectives: (i) To obtain a sensitivity estimate ≥60% with 95% CI lower limit ≥50% in the whole group of cancer cases (DCIS, IDC and ILC); also to obtain a sensitivity estimate with the same properties in the subset of cases with invasive cancer (IDC and ILC). (ii) To obtain a specificity estimate ≥90% in controls with 95% CI lower limit ≥85%. Part 2 will examine the yield of cancer detection by MRI/biopsy among women who have a positive OctavaPink test result in the dense breast negative mammography population. Objectives: (i) To compare the yield of cancer detection via MRI/biopsy among women with a positive OctavaPink test versus a negative OctavaPink test result. (ii) To estimate the proportion of patients who are positive for the test in the target population Part 3 will assess sensitivity of OctavaPink test in an enriched population of women with dense breasts and negative mammography. Objectives: To obtain an estimate of sensitivity in women with dense breast tissue and negative mammography that is broadly consistent with that found in the dense breast population (but not necessarily negative mammogram) in Parts 1A and 1B.

Eligibility

Minimum Age: 30 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: Yes

Locations

Detroit Clinical Research Center, Detroit, Michigan, United States

MD Anderson cancer center, Houston, Texas, United States

Shaarey Tzedek, Jerusalem, , Israel

Shiba, Ramat Gan, , Israel

Kaplan medical center, Rehovot, , Israel

Sourasky medical center, Tel Aviv, , Israel

Fondazione Carlo ferri, Rome, , Italy

Contact Details

Name: Edith Perez, Prof.

Affiliation: Mayo Clinic, Jacksonville Florida USA

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: